116 related articles for article (PubMed ID: 10358081)
1. Structural insight into a quinolone-topoisomerase II-DNA complex. Further evidence for a 2:2 quinobenzoxazine-mg2+ self-assembly model formed in the presence of topoisomerase ii.
Kwok Y; Zeng Q; Hurley LH
J Biol Chem; 1999 Jun; 274(24):17226-35. PubMed ID: 10358081
[TBL] [Abstract][Full Text] [Related]
2. Self-assembly of a quinobenzoxazine-Mg2+ complex on DNA: a new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex.
Fan JY; Sun D; Yu H; Kerwin SM; Hurley LH
J Med Chem; 1995 Feb; 38(3):408-24. PubMed ID: 7853333
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites.
Kwok Y; Zeng Q; Hurley LH
Proc Natl Acad Sci U S A; 1998 Nov; 95(23):13531-6. PubMed ID: 9811834
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of psorospermin/quinobenzoxazine hybrids as structurally novel antitumor agents.
Kim MY; Na Y; Vankayalapati H; Gleason-Guzman M; Hurley LH
J Med Chem; 2003 Jul; 46(14):2958-72. PubMed ID: 12825936
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II site-directed alkylation of DNA by psorospermin and its effect on topoisomerase II-mediated DNA cleavage.
Kwok Y; Hurley LH
J Biol Chem; 1998 Dec; 273(49):33020-6. PubMed ID: 9830055
[TBL] [Abstract][Full Text] [Related]
6. The quinobenzoxazines: relationship between DNA binding and biological activity.
Kwok Y; Sun D; Clement JJ; Hurley LH
Anticancer Drug Des; 1999 Oct; 14(5):443-50. PubMed ID: 10766299
[TBL] [Abstract][Full Text] [Related]
7. Efficient, Mg(2+)-dependent photochemical DNA cleavage by the antitumor quinobenzoxazine (S)-A-62176.
Yu H; Kwok Y; Hurley LH; Kerwin SM
Biochemistry; 2000 Aug; 39(33):10236-46. PubMed ID: 10956013
[TBL] [Abstract][Full Text] [Related]
8. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
9. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
10. Interactions between fluoroquinolones, Mg2+, DNA and DNA gyrase, studied by phase partitioning in an aqueous two-phase system and by affinity chromatography.
Khac SB; Moreau NJ
J Chromatogr A; 1994 May; 668(1):241-7. PubMed ID: 7516247
[TBL] [Abstract][Full Text] [Related]
11. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex.
Hiasa H; Yousef DO; Marians KJ
J Biol Chem; 1996 Oct; 271(42):26424-9. PubMed ID: 8824300
[TBL] [Abstract][Full Text] [Related]
12. DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives.
Huff AC; Robinson RG; Evans AC; Selander KN; Wentland MP; Rake JB; Coughlin SA
Anticancer Drug Des; 1995 Apr; 10(3):251-76. PubMed ID: 7748459
[TBL] [Abstract][Full Text] [Related]
13. DNA abasic lesions in a different light: solution structure of an endogenous topoisomerase II poison.
Cline SD; Jones WR; Stone MP; Osheroff N
Biochemistry; 1999 Nov; 38(47):15500-7. PubMed ID: 10569932
[TBL] [Abstract][Full Text] [Related]
14. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes.
Shen LL; Kohlbrenner WE; Weigl D; Baranowski J
J Biol Chem; 1989 Feb; 264(5):2973-8. PubMed ID: 2536729
[TBL] [Abstract][Full Text] [Related]
16. Determination of the importance of the stereochemistry of psorospermin in topoisomerase II-induced alkylation of DNA and in vitro and in vivo biological activity.
Fellows IM; Schwaebe M; Dexheimer TS; Vankayalapati H; Gleason-Guzman M; Whitten JP; Hurley LH
Mol Cancer Ther; 2005 Nov; 4(11):1729-39. PubMed ID: 16275994
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of site-specific topoisomerase II-mediated DNA cleavage by an N-methylpyrrolecarboxamide-anilinoacridine conjugate: relation to DNA binding.
Fossé P; René B; Saucier JM; Hénichart JP; Waring MJ; Colson P; Houssier C; Bailly C
Biochemistry; 1994 Aug; 33(33):9865-74. PubMed ID: 8060993
[TBL] [Abstract][Full Text] [Related]
18. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.
Dong J; Walker J; Nitiss JL
J Biol Chem; 2000 Mar; 275(11):7980-7. PubMed ID: 10713116
[TBL] [Abstract][Full Text] [Related]
19. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.
Zeng Q; Kwok Y; Kerwin SM; Mangold G; Hurley LH
J Med Chem; 1998 Oct; 41(22):4273-8. PubMed ID: 9784102
[TBL] [Abstract][Full Text] [Related]
20. Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
Osheroff N; Corbett AH; Elsea SH; Westergaard M
Cancer Chemother Pharmacol; 1994; 34 Suppl():S19-25. PubMed ID: 8070023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
